Longeveron announces completion of enrollment in Phase 2a trial of Lomecel-B

Longeveron announced the completion of enrollment in its Phase 2a trial of Lomecel-BTM in patients with mild Alzheimer’s Disease, AD. "We are pleased to have completed enrollment in our Phase 2a study of Lomecel-BTM for Alzheimer’s Disease. We look forward to building on our Phase 1b study, which met its primary endpoint of safety and was published in a leading journal, Alzheimer’s and Dementia, the Journal of the Alzheimer’s Association this year. We are excited to advance our program designed to assess the therapeutic potential of Lomecel-BTM in patients with AD," said Chris Min, M.D., Ph.D., Interim Chief Executive Officer and Chief Medical Officer of Longeveron.